(Q36377258)

13 August 2017

Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo (English)

1 reference

13 August 2017

0 references

Powell DR

1

1 reference

13 August 2017

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

1

1 reference

13 August 2017

89-108

1 reference

The knockout mouse project

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Knockouts model the 100 best-selling drugs--will they model the next 100?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Long-term administration of dexfenfluramine to genetically obese (ob/ob) and lean mice: body weight and brain serotonin changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Treatment of obesity: an update on anti-obesity medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Targeted disruption of the melanocortin-4 receptor results in obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Characterization of the genomic structure and expression of the mouse Apex2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Binge eating as a major phenotype of melanocortin 4 receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Mice lacking melanin-concentrating hormone are hypophagic and lean

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Beta-adrenergic receptors and regulation of energy expenditure: a family affair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Tremor and the anti-obesity drug BRL 26830A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Targeted disruption of the beta 3-adrenergic receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Strain-specific response to beta 3-adrenergic receptor agonist treatment of diet-induced obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Behavioral characterization of mice lacking histamine H(3) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Increased adipose tissue in male and female estrogen receptor-alpha knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

The emergence of the metabolic syndrome with menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

The thermogenic effect of thyroid hormone and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Quantitative and qualitative effects of l-triiodothyronine in massive obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Treatment of obesity with triiodothyronine and a very-low-calorie liquid formula diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A descriptive study of weight loss maintenance: 6 and 15 year follow-up of initially overweight adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Thyroid hormone receptors: lessons from knockout and knock-in mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

An anorexic lipid mediator regulated by feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Neurotoxic effects of +/-fenfluramine and phenteramine, alone and in combination, on monoamine neurons in the mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Thermoregulatory and metabolic phenotypes of mice lacking noradrenaline and adrenaline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Decreased neonatal dietary fat absorption and T cell cytotoxicity in pancreatic lipase-related protein 2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

C75 inhibits food intake by increasing CNS glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Defective STAT signaling by the leptin receptor in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Physiological response to long-term peripheral and central leptin infusion in lean and obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Leptin resistance in mice is determined by gender and duration of exposure to high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

The role of leptin resistance in the lipid abnormalities of aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Disruption of the CNTF gene results in motor neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A null mutation in the human CNTF gene is not causally related to neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Amylin: a novel action in the brain to reduce body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Does neuropeptide Y contribute to the anorectic action of amylin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Initial sequencing and comparative analysis of the mouse genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

A central role for JNK in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

Rapid development of tolerance to the behavioural actions of cholecystokinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2006.00220.X

10.1111/J.1467-789X.2006.00220.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16436105